Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Zhang

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cancer Chemotherapy and Pharmacology|March 8, 2013
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignanciesLaura Q M Chow, Derek I Jonker, Grace K Dy, et al.
Journal of Neuro-Oncology|March 13, 2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.
Cancer Research|December 26, 2003
Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factorsAndrew W Snowden, Lei Zhang, Fyodor Urnov, et al.
Nature Cell Biology|May 8, 2023
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleusAlbertas Navickas, Hosseinali Asgharian, Juliane Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignanciesAmita Patnaik, S Gail Eckhardt, Elzbieta Izbicka, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2003
Zinc-finger protein-targeted gene regulation: genomewide single-gene specificitySiyuan Tan, Dmitry Guschin, Albert Davalos, et al.
Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.
Nucleic Acids Research|September 29, 2025
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendationsJesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cancer Chemotherapy and Pharmacology|March 8, 2013
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignanciesLaura Q M Chow, Derek I Jonker, Grace K Dy, et al.
Journal of Neuro-Oncology|March 13, 2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.
Cancer Research|December 26, 2003
Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factorsAndrew W Snowden, Lei Zhang, Fyodor Urnov, et al.
Nature Cell Biology|May 8, 2023
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleusAlbertas Navickas, Hosseinali Asgharian, Juliane Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignanciesAmita Patnaik, S Gail Eckhardt, Elzbieta Izbicka, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2003
Zinc-finger protein-targeted gene regulation: genomewide single-gene specificitySiyuan Tan, Dmitry Guschin, Albert Davalos, et al.
Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.
Nucleic Acids Research|September 29, 2025
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendationsJesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, et al.
Pageof 7